Uncovering Answers to Protect Patients' Health
As an innovative, research-driven pharmaceutical company Boehringer Ingelheim conducts and sponsors clinical trials to establish the safety and efficacy of the drugs we develop, either for use in their initial indication or in additional indications. In 2008, Boehringer Ingelheim presents results from large-scale, randomised, controlled landmark trials in cardiovascular, respiratory and cerebrovascular diseases. These landmark trials are running in more than 40 countries and involve more than 70,000 patients.
About Clinical Trials
Boehringer Ingelheim conducts and sponsors clinical trials to establish safety and efficacy of the drugs we develop, either for use in their initial indication or in additional indications. read more
Boehringer Ingelheim Landmark Trials
ONTARGET®
This groundbreaking study programme explores therapeutic options in cardiovascular protection.
read more
PRoFESS®
The largest ever trial exploring therapeutic options in prevention of secondary stroke.
read more
UPLIFT®
UPLIFT® (Understanding Potential Long-term impacts on Function with Tiotropium) is a four-year landmark trial involving nearly 6.000 patients with COPD.
read more
RE-LY™
This trial evaluates the long-term anticoagulant therapy with dabigatran etexilate.
read more
